![Metabolites | Free Full-Text | Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target Metabolites | Free Full-Text | Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target](https://pub.mdpi-res.com/metabolites/metabolites-11-00690/article_deploy/html/images/metabolites-11-00690-g003.png?1634700054)
Metabolites | Free Full-Text | Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
![IJMS | Free Full-Text | The Association between Apolipoprotein B, Cardiovascular Risk Factors and Subclinical Atherosclerosis—Findings from the SEPHAR National Registry on Hypertension in Romania IJMS | Free Full-Text | The Association between Apolipoprotein B, Cardiovascular Risk Factors and Subclinical Atherosclerosis—Findings from the SEPHAR National Registry on Hypertension in Romania](https://pub.mdpi-res.com/ijms/ijms-24-02813/article_deploy/html/images/ijms-24-02813-g001.png?1675257804)
IJMS | Free Full-Text | The Association between Apolipoprotein B, Cardiovascular Risk Factors and Subclinical Atherosclerosis—Findings from the SEPHAR National Registry on Hypertension in Romania
![Apolipoprotein B-100 (ApoB-100) ELISA, 27181 (RUO) | Human ApoB-100 (Apolipoprotein B-100) Competitive Enzyme-linked Immuno-sorbent Assay Kit IBL-America Apolipoprotein B-100 (ApoB-100) ELISA, 27181 (RUO) | Human ApoB-100 (Apolipoprotein B-100) Competitive Enzyme-linked Immuno-sorbent Assay Kit IBL-America](https://cdn11.bigcommerce.com/s-dpaty9ionu/images/stencil/500x659/products/5541/13952/apob1__47825.1635531642.png?c=2)
Apolipoprotein B-100 (ApoB-100) ELISA, 27181 (RUO) | Human ApoB-100 (Apolipoprotein B-100) Competitive Enzyme-linked Immuno-sorbent Assay Kit IBL-America
![The LDL-C/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease - ScienceDirect The LDL-C/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S002191502100246X-ga1.jpg)
The LDL-C/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease - ScienceDirect
![JAMA on Twitter: "Apolipoprotein B (apoB) particles are the basic unit of injury to the arterial wall, and there is now substantial evidence that apoB more accurately measures atherogenic risk than LDL JAMA on Twitter: "Apolipoprotein B (apoB) particles are the basic unit of injury to the arterial wall, and there is now substantial evidence that apoB more accurately measures atherogenic risk than LDL](https://pbs.twimg.com/media/ENsf-PqXUAAlb8P.jpg)
JAMA on Twitter: "Apolipoprotein B (apoB) particles are the basic unit of injury to the arterial wall, and there is now substantial evidence that apoB more accurately measures atherogenic risk than LDL
![PDF] Correlation between Apolipoprotein B-to-Apolipoprotein A1 Ratio and Total-to-HDL-Cholesterol Ratio in a Healthy Population: Should Castelli Index be Updated? | Semantic Scholar PDF] Correlation between Apolipoprotein B-to-Apolipoprotein A1 Ratio and Total-to-HDL-Cholesterol Ratio in a Healthy Population: Should Castelli Index be Updated? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/220ad52daf16f336519ec27191f3ef775108fa99/3-Table2-1.png)
PDF] Correlation between Apolipoprotein B-to-Apolipoprotein A1 Ratio and Total-to-HDL-Cholesterol Ratio in a Healthy Population: Should Castelli Index be Updated? | Semantic Scholar
![Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis. | Semantic Scholar Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/51e5c4cbdb9a90f37f4a17cb18b665af57f799cc/4-Figure3-1.png)
Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis. | Semantic Scholar
![Metabolites | Free Full-Text | Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target Metabolites | Free Full-Text | Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target](https://pub.mdpi-res.com/metabolites/metabolites-11-00690/article_deploy/html/images/metabolites-11-00690-g001.png?1634700054)
Metabolites | Free Full-Text | Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
![Physiological Bases for the Superiority of Apolipoprotein B Over Low‐Density Lipoprotein Cholesterol and Non–High‐Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk | Journal of the American Heart Association Physiological Bases for the Superiority of Apolipoprotein B Over Low‐Density Lipoprotein Cholesterol and Non–High‐Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/29bf0a77-ae42-433a-b5f3-6960a482c256/jah37782-fig-0001.png)
Physiological Bases for the Superiority of Apolipoprotein B Over Low‐Density Lipoprotein Cholesterol and Non–High‐Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk | Journal of the American Heart Association
![Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis. | Semantic Scholar Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/51e5c4cbdb9a90f37f4a17cb18b665af57f799cc/3-Figure2-1.png)
Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis. | Semantic Scholar
Dr.Túlio Sperb - RELAÇÃO APO B / APO A!!! Fiz um stories essa semana mostrando que a minha relação tinha reduzido de 0.96 para 0.57 e choveu no meu direct "Parabéns, mas
![The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence - WALLDIUS - 2006 - Journal of Internal Medicine - The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence - WALLDIUS - 2006 - Journal of Internal Medicine -](https://onlinelibrary.wiley.com/cms/asset/78bd6665-5f2a-447a-a3a4-b811cabad8f2/joim_1643_f1.gif)
The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence - WALLDIUS - 2006 - Journal of Internal Medicine -
![Proteomic studies on apoB‐containing lipoprotein in cardiovascular research: A comprehensive review - Gianazza - Mass Spectrometry Reviews - Wiley Online Library Proteomic studies on apoB‐containing lipoprotein in cardiovascular research: A comprehensive review - Gianazza - Mass Spectrometry Reviews - Wiley Online Library](https://analyticalsciencejournals.onlinelibrary.wiley.com/cms/asset/ebdea48e-db4a-4b33-b145-eaa9a8cfe4ab/mas21747-fig-0001-m.jpg)
Proteomic studies on apoB‐containing lipoprotein in cardiovascular research: A comprehensive review - Gianazza - Mass Spectrometry Reviews - Wiley Online Library
![SciELO - Brasil - Índice apo B/apo A-I e predição de risco cardiovascular Índice apo B/apo A-I e predição de risco cardiovascular SciELO - Brasil - Índice apo B/apo A-I e predição de risco cardiovascular Índice apo B/apo A-I e predição de risco cardiovascular](https://minio.scielo.br/documentstore/1678-4170/CXGNHcpCGDHTZpV7YdYKNLs/d2169b656de935554617db5f8bd94873eb902e12.jpg)